Overview

A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of docetaxel and CNTO 328 when given together as a treatment. The second goal of this study is to determine if a combination of docetaxel and CNTO 328 has an effect on prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Centocor, Inc.
Treatments:
Antibodies, Monoclonal
Docetaxel
Hormones
Siltuximab